Cyclophosphamide, an alkylating agent used in the treatment of LN, is associated with high oxidative stress, which can lead to hepatotoxicity and myelotoxicity, and Nrf2 activation may ameliorate these effects [6,10]. The gene discussed is NFE2L2; the disease is lobular neoplasia.